129 related articles for article (PubMed ID: 37742945)
21.
Saini U; Suarez AA; Naidu S; Wallbillich JJ; Bixel K; Wanner RA; Bice J; Kladney RD; Lester J; Karlan BY; Goodfellow PJ; Cohn DE; Selvendiran K
Cancer Res; 2018 Apr; 78(7):1739-1750. PubMed ID: 29339537
[TBL] [Abstract][Full Text] [Related]
22. Disease Distribution in Low-stage Tubo-ovarian High-grade Serous Carcinoma (HGSC): Implications for Assigning Primary Site and FIGO Stage.
Singh N; Benson JL; Gan C; Anglesio M; Arora R; Faruqi AZ; Hirschowitz L; Kommoss F; Scott K; Trevisan G; Leen SLS; Wilkinson N; Gilks CB; McCluggage WG
Int J Gynecol Pathol; 2018 Jul; 37(4):324-330. PubMed ID: 28787323
[TBL] [Abstract][Full Text] [Related]
23. Claudin-10 is a new candidate prognostic marker in metastatic high-grade serous carcinoma.
Davidson B; Doutel D; Holth A; Nymoen DA
Virchows Arch; 2023 Jun; 482(6):975-982. PubMed ID: 37067588
[TBL] [Abstract][Full Text] [Related]
24. MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma.
Kang EY; Millstein J; Popovic G; Meagher NS; Bolithon A; Talhouk A; Chiu DS; Anglesio MS; Leung B; Tang K; Lambie N; Pavanello M; Da-Anoy A; Lambrechts D; Loverix L; Olbrecht S; Bisinotto C; Garcia-Donas J; Ruiz-Llorente S; Yagüe-Fernandez M; Edwards RP; Elishaev E; Olawaiye A; Taylor S; Ataseven B; du Bois A; Harter P; Lester J; Høgdall CK; Armasu SM; Huang Y; Vierkant RA; Wang C; Winham SJ; Heublein S; Kommoss FKF; Cramer DW; Sasamoto N; van-Wagensveld L; Lycke M; Mateoiu C; Joseph J; Pike MC; Odunsi K; Tseng CC; Pearce CL; Bilic S; Conrads TP; Hartmann A; Hein A; Jones ME; Leung Y; Beckmann MW; Ruebner M; Schoemaker MJ; Terry KL; El-Bahrawy MA; Coulson P; Etter JL; LaVigne-Mager K; Andress J; Grube M; Fischer A; Neudeck N; Robertson G; Farrell R; Barlow E; Quinn C; Hettiaratchi A; Casablanca Y; Erber R; Stewart CJR; Tan A; Yu Y; Boros J; Brand AH; Harnett PR; Kennedy CJ; Nevins N; Morgan T; Fasching PA; Vergote I; Swerdlow AJ; Candido Dos Reis FJ; Maxwell GL; Neuhausen SL; Barquin-Garcia A; Modugno F; Moysich KB; Crowe PJ; Hirasawa A; Heitz F; Karlan BY; Goode EL; Sinn P; Horlings HM; Høgdall E; Sundfeldt K; Kommoss S; Staebler A; Wu AH; Cohen PA; DeFazio A; Lee CH; Steed H; Le ND; Gayther SA; Lawrenson K; Pharoah PDP; Konecny G; Cook LS; Ramus SJ; Kelemen LE; Köbel M
Virchows Arch; 2022 Apr; 480(4):855-871. PubMed ID: 34782936
[TBL] [Abstract][Full Text] [Related]
25. Gene expression profiles of ovarian low-grade serous carcinoma resemble those of fallopian tube epithelium.
Qiu C; Lu N; Wang X; Zhang Q; Yuan C; Yan S; Dongol S; Li Y; Sun X; Sun C; Zhang Z; Zheng W; Kong B
Gynecol Oncol; 2017 Dec; 147(3):634-641. PubMed ID: 28965696
[TBL] [Abstract][Full Text] [Related]
26. LRP1B Expression as a Putative Predictor of Response to Pegylated Liposomal Doxorubicin Treatment in Ovarian Cancer.
Dionísio de Sousa IJ; Cunha AI; Saraiva IA; Portugal RV; Gimba ERP; Guimarães M; Prazeres H; Lopes JM; Soares P; Lima RT
Pathobiology; 2021; 88(6):400-411. PubMed ID: 34689147
[TBL] [Abstract][Full Text] [Related]
27. Chemotherapy-associated foam cell aggregates as a prognostic factor in patients with pelvic high-grade serous carcinoma receiving neo-adjuvant chemotherapy.
Kojima N; Kuno I; Ushigusa T; Kato T; Yoshida H
Virchows Arch; 2020 Sep; 477(3):429-436. PubMed ID: 32103350
[TBL] [Abstract][Full Text] [Related]
28. Immunotyping in tubo-ovarian high-grade serous carcinoma by PD-L1 and CD8+ T-lymphocytes predicts disease-free survival.
Bansal A; Srinivasan R; Rohilla M; Rai B; Rajwanshi A; Suri V; Chandra Saha S
APMIS; 2021 May; 129(5):254-264. PubMed ID: 33455015
[TBL] [Abstract][Full Text] [Related]
29. Clinicopathological prognostic parameters in patients with tubo-ovarian carcinoma effusions.
Davidson B; Elstrand MB
Cytopathology; 2022 Jul; 33(4):479-492. PubMed ID: 35398934
[TBL] [Abstract][Full Text] [Related]
30. Morphology and tumour-infiltrating lymphocytes in high-stage, high-grade serous ovarian carcinoma correlated with long-term survival.
Darb-Esfahani S; Kolaschinski I; Trillsch F; Mahner S; Concin N; Vergote I; Van Nieuwenhuysen E; Achimas-Cadariu P; Glajzer J; Woopen H; Wienert S; Taube ET; Stanske M; Kulbe H; Denkert C; Sehouli J; Braicu EI
Histopathology; 2018 Dec; 73(6):1002-1012. PubMed ID: 30007074
[TBL] [Abstract][Full Text] [Related]
31. Increased FOXJ1 protein expression is associated with improved overall survival in high-grade serous ovarian carcinoma: an Ovarian Tumor Tissue Analysis Consortium Study.
Weir A; Kang EY; Meagher NS; Nelson GS; Ghatage P; Lee CH; Riggan MJ; Gentry-Maharaj A; Ryan A; Singh N; Widschwendter M; Alsop J; Anglesio MS; Beckmann MW; Berger J; Bisinotto C; Boros J; Brand AH; Brenton JD; Brooks-Wilson A; Carney ME; Cunningham JM; Cushing-Haugen KL; Cybulski C; Elishaev E; Erber R; Fereday S; Fischer A; Paz-Ares L; Gayarre J; Gilks BC; Grube M; Harnett PR; Harris HR; Hartmann A; Hein A; Hendley J; Hernandez BY; Heublein S; Huang Y; Huzarski T; Jakubowska A; Jimenez-Linan M; Kennedy CJ; Kommoss FKF; Koziak JM; Kraemer B; Le ND; Lesnock J; Lester J; Lubiński J; Menkiszak J; Ney B; Olawaiye A; Orsulic S; Osorio A; Robles-Díaz L; Ruebner M; Shah M; Sharma R; Shvetsov YB; Steed H; Talhouk A; Taylor SE; Traficante N; Vierkant RA; Wang C; Wilkens LR; Winham SJ; Benitez J; Berchuck A; Bowtell DD; Candido Dos Reis FJ; Cook LS; DeFazio A; ; Doherty JA; Fasching PA; García MJ; Goode EL; Goodman MT; Gronwald J; Huntsman DG; Karlan BY; Kommoss S; Modugno F; Schildkraut JM; Sinn HP; Staebler A; Kelemen LE; Ford CE; Menon U; Pharoah PDP; Köbel M; Ramus SJ
Br J Cancer; 2023 Jan; 128(1):137-147. PubMed ID: 36323878
[TBL] [Abstract][Full Text] [Related]
32. [Current FIGO staging classification for cancer of ovary, fallopian tube and peritoneum].
Šišovská I; Minář L; Felsinger M; Anton M; Bednaříková M; Hausnerová J; Jandáková E; Weinberger V
Ceska Gynekol; 2017; 82(3):230-236. PubMed ID: 28593778
[TBL] [Abstract][Full Text] [Related]
33. CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study.
Kang EY; Weir A; Meagher NS; Farrington K; Nelson GS; Ghatage P; Lee CH; Riggan MJ; Bolithon A; Popovic G; Leung B; Tang K; Lambie N; Millstein J; Alsop J; Anglesio MS; Ataseven B; Barlow E; Beckmann MW; Berger J; Bisinotto C; Bösmüller H; Boros J; Brand AH; Brooks-Wilson A; Brucker SY; Carney ME; Casablanca Y; Cazorla-Jiménez A; Cohen PA; Conrads TP; Cook LS; Coulson P; Courtney-Brooks M; Cramer DW; Crowe P; Cunningham JM; Cybulski C; Darcy KM; El-Bahrawy MA; Elishaev E; Erber R; Farrell R; Fereday S; Fischer A; García MJ; Gayther SA; Gentry-Maharaj A; Gilks CB; ; Grube M; Harnett PR; Harrington SP; Harter P; Hartmann A; Hecht JL; Heikaus S; Hein A; Heitz F; Hendley J; Hernandez BY; Polo SH; Heublein S; Hirasawa A; Høgdall E; Høgdall CK; Horlings HM; Huntsman DG; Huzarski T; Jewell A; Jimenez-Linan M; Jones ME; Kaufmann SH; Kennedy CJ; Khabele D; Kommoss FKF; Kruitwagen RFPM; Lambrechts D; Le ND; Lener M; Lester J; Leung Y; Linder A; Loverix L; Lubiński J; Madan R; Maxwell GL; Modugno F; Neuhausen SL; Olawaiye A; Olbrecht S; Orsulic S; Palacios J; Pearce CL; Pike MC; Quinn CM; Mohan GR; Rodríguez-Antona C; Ruebner M; Ryan A; Salfinger SG; Sasamoto N; Schildkraut JM; Schoemaker MJ; Shah M; Sharma R; Shvetsov YB; Singh N; Sonke GS; Steele L; Stewart CJR; Sundfeldt K; Swerdlow AJ; Talhouk A; Tan A; Taylor SE; Terry KL; Tołoczko A; Traficante N; Van de Vijver KK; van der Aa MA; Van Gorp T; Van Nieuwenhuysen E; van-Wagensveld L; Vergote I; Vierkant RA; Wang C; Wilkens LR; Winham SJ; Wu AH; Benitez J; Berchuck A; Candido Dos Reis FJ; DeFazio A; Fasching PA; Goode EL; Goodman MT; Gronwald J; Karlan BY; Kommoss S; Menon U; Sinn HP; Staebler A; Brenton JD; Bowtell DD; Pharoah PDP; Ramus SJ; Köbel M
Cancer; 2023 Mar; 129(5):697-713. PubMed ID: 36572991
[TBL] [Abstract][Full Text] [Related]
34. Incidence of germline BRCA1/2 mutations in women with tubo-ovarian high-grade serous carcinomas with and without serous tubal intra-epithelial carcinomas.
Dowson CB; Stewart C; O'Sullivan S; Pachter N; Schofield L; Cohen PA
Int J Gynecol Cancer; 2020 Jan; 30(1):94-99. PubMed ID: 31699802
[TBL] [Abstract][Full Text] [Related]
35. Targeted Sequencing of Tubo-ovarian and Peritoneal High-grade Serous Carcinoma With Wild-type p53 Immunostaining Pattern.
Kim HN; Woo HY; DO SI; Kim HS
In Vivo; 2019; 33(5):1485-1492. PubMed ID: 31471396
[TBL] [Abstract][Full Text] [Related]
36. Clinical significance of L1CAM expression in metastatic tubo-ovarian high-grade serous carcinoma.
Dos Santos MV; Holth A; Lindemann K; Staff AC; Davidson B
Gynecol Oncol; 2023 Sep; 176():76-81. PubMed ID: 37478615
[TBL] [Abstract][Full Text] [Related]
37. Should All Cases of High-Grade Serous Ovarian, Tubal, and Primary Peritoneal Carcinomas Be Reclassified as Tubo-Ovarian Serous Carcinoma?
Moss EL; Evans T; Pearmain P; Askew S; Singh K; Chan KK; Ganesan R; Hirschowitz L
Int J Gynecol Cancer; 2015 Sep; 25(7):1201-7. PubMed ID: 26035124
[TBL] [Abstract][Full Text] [Related]
38. Chemotherapy Response Score: Development and Validation of a System to Quantify Histopathologic Response to Neoadjuvant Chemotherapy in Tubo-Ovarian High-Grade Serous Carcinoma.
Böhm S; Faruqi A; Said I; Lockley M; Brockbank E; Jeyarajah A; Fitzpatrick A; Ennis D; Dowe T; Santos JL; Cook LS; Tinker AV; Le ND; Gilks CB; Singh N
J Clin Oncol; 2015 Aug; 33(22):2457-63. PubMed ID: 26124480
[TBL] [Abstract][Full Text] [Related]
39. Outcomes of Non-High Grade Serous Carcinoma after Neoadjuvant Chemotherapy for Advanced-Stage Ovarian Cancer: Single-Institution Experience.
Chung YS; Lee JY; Kim HS; Nam EJ; Kim SW; Kim YT
Yonsei Med J; 2018 Oct; 59(8):930-936. PubMed ID: 30187699
[TBL] [Abstract][Full Text] [Related]
40. Key features of extrauterine pelvic serous tumours (fallopian tube, ovary, and peritoneum).
Delair D; Soslow RA
Histopathology; 2012 Sep; 61(3):329-39. PubMed ID: 22372521
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]